Revenue Breakdown
Composition ()
No data
Revenue Streams
Mirum Pharmaceuticals Inc (MIRM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Livmarli, accounting for 69.3% of total sales, equivalent to $92.23M. Another important revenue stream is Bile Acid Medicines. Understanding this composition is critical for investors evaluating how MIRM navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Mirum Pharmaceuticals Inc maintains a gross margin of 80.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.96%, while the net margin is 2.18%. These profitability ratios, combined with a Return on Equity (ROE) of -15.81%, provide a clear picture of how effectively MIRM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MIRM competes directly with industry leaders such as TGTX and CORT. With a market capitalization of $6.10B, it holds a leading position in the sector. When comparing efficiency, MIRM's gross margin of 80.80% stands against TGTX's 82.63% and CORT's 97.79%. Such benchmarking helps identify whether Mirum Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
